Brachytherapy
Brachytherapy is a radiation therapy with 137 clinical trials. Currently 25 active trials ongoing. Historical success rate of 76.7%.
Success Metrics
Based on 56 completed trials
Phase Distribution
Phase Distribution
29
Early Stage
37
Mid Stage
31
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
71.8%
56 of 78 finished
28.2%
22 ended early
25
trials recruiting
137
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
Brachytherapy for Prostatic Carcinoma Patients
Clinical Trials (137)
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
Brachytherapy for Prostatic Carcinoma Patients
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer
Retinoblastoma Consolidation in Egyptians
Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer
3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
Effect of Bladder Distension on Dosimetry in Brachytherapy of Cervical Cancer
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 137